These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 15239132)

  • 1. CHEK2 variant I157T may be associated with increased breast cancer risk.
    Kilpivaara O; Vahteristo P; Falck J; Syrjäkoski K; Eerola H; Easton D; Bartkova J; Lukas J; Heikkilä P; Aittomäki K; Holli K; Blomqvist C; Kallioniemi OP; Bartek J; Nevanlinna H
    Int J Cancer; 2004 Sep; 111(4):543-7. PubMed ID: 15239132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of two mutations in the CHEK2 gene with breast cancer.
    Bogdanova N; Enssen-Dubrowinskaja N; Feshchenko S; Lazjuk GI; Rogov YI; Dammann O; Bremer M; Karstens JH; Sohn C; Dörk T
    Int J Cancer; 2005 Aug; 116(2):263-6. PubMed ID: 15810020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CHEK2 I157T variant and breast cancer susceptibility: a systematic review and meta-analysis.
    Liu C; Wang Y; Wang QS; Wang YJ
    Asian Pac J Cancer Prev; 2012; 13(4):1355-60. PubMed ID: 22799331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis.
    Han FF; Guo CL; Liu LH
    DNA Cell Biol; 2013 Jun; 32(6):329-35. PubMed ID: 23713947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.
    Bayram S; Topaktaş M; Akkız H; Bekar A; Akgöllü E
    Cancer Epidemiol; 2012 Oct; 36(5):453-7. PubMed ID: 22521562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHEK2 I157T associates with familial and sporadic colorectal cancer.
    Kilpivaara O; Alhopuro P; Vahteristo P; Aaltonen LA; Nevanlinna H
    J Med Genet; 2006 Jul; 43(7):e34. PubMed ID: 16816021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry.
    Bernstein JL; Teraoka SN; John EM; Andrulis IL; Knight JA; Lapinski R; Olson ER; Wolitzer AL; Seminara D; Whittemore AS; Concannon P
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):348-52. PubMed ID: 16492927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CHEK2 gene and inherited breast cancer susceptibility.
    Nevanlinna H; Bartek J
    Oncogene; 2006 Sep; 25(43):5912-9. PubMed ID: 16998506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
    J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosomal radiosensitivity of breast cancer with a CHEK2 mutation.
    Baeyens A; Claes K; Willems P; De Ruyck K; Thierens H; Vral A
    Cancer Genet Cytogenet; 2005 Dec; 163(2):106-12. PubMed ID: 16337852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population.
    Osorio A; Rodríguez-López R; Díez O; de la Hoya M; Ignacio Martínez J; Vega A; Esteban-Cardeñosa E; Alonso C; Caldés T; Benítez J
    Int J Cancer; 2004 Jan; 108(1):54-6. PubMed ID: 14618615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHEK2 I157T and colorectal cancer in Bulgaria.
    Konstantinova D; Kadiyska T; Sokolova V; Kaneva R; Mirchev M; Savov A; Aleksandrova A; Nedin D; Kostadinov E; Damyanov D; Kremensky I; Mitev V
    J BUON; 2010; 15(2):314-7. PubMed ID: 20658728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
    Muranen TA; Blomqvist C; Dörk T; Jakubowska A; Heikkilä P; Fagerholm R; Greco D; Aittomäki K; Bojesen SE; Shah M; Dunning AM; Rhenius V; Hall P; Czene K; Brand JS; Darabi H; Chang-Claude J; Rudolph A; Nordestgaard BG; Couch FJ; Hart SN; Figueroa J; García-Closas M; Fasching PA; Beckmann MW; Li J; Liu J; Andrulis IL; Winqvist R; Pylkäs K; Mannermaa A; Kataja V; Lindblom A; Margolin S; Lubinski J; Dubrowinskaja N; Bolla MK; Dennis J; Michailidou K; Wang Q; Easton DF; Pharoah PD; Schmidt MK; Nevanlinna H
    Breast Cancer Res; 2016 Oct; 18(1):98. PubMed ID: 27716369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.
    Kilpivaara O; Bartkova J; Eerola H; Syrjäkoski K; Vahteristo P; Lukas J; Blomqvist C; Holli K; Heikkilä P; Sauter G; Kallioniemi OP; Bartek J; Nevanlinna H
    Int J Cancer; 2005 Feb; 113(4):575-80. PubMed ID: 15472904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHEK2 gene alterations in the forkhead-associated domain, 1100delC and del5395 do not modify the risk of sporadic pancreatic cancer.
    Mohelnikova-Duchonova B; Havranek O; Hlavata I; Foretova L; Kleibl Z; Pohlreich P; Soucek P
    Cancer Epidemiol; 2010 Oct; 34(5):656-8. PubMed ID: 20643596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
    Domagala P; Wokolorczyk D; Cybulski C; Huzarski T; Lubinski J; Domagala W
    Breast Cancer Res Treat; 2012 Apr; 132(3):937-45. PubMed ID: 21701879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.
    Schutte M; Seal S; Barfoot R; Meijers-Heijboer H; Wasielewski M; Evans DG; Eccles D; Meijers C; Lohman F; Klijn J; van den Ouweland A; Futreal PA; Nathanson KL; Weber BL; Easton DF; Stratton MR; Rahman N;
    Am J Hum Genet; 2003 Apr; 72(4):1023-8. PubMed ID: 12610780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
    Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
    Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women.
    Friedrichsen DM; Malone KE; Doody DR; Daling JR; Ostrander EA
    Breast Cancer Res; 2004; 6(6):R629-35. PubMed ID: 15535844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing Cancer Risk Management between Females with Truncating
    Garmendia D; Weidner A; Venton L; Pal T
    Genes (Basel); 2024 Jul; 15(7):. PubMed ID: 39062660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.